Selecta Biosciences, Inc. Appoints Takashi Kei Kishimoto, Ph.D., as Chief Scientific Officer

Published: Aug 31, 2011

WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc., a biopharmaceutical company developing novel targeted vaccines and immunotherapies, announced today that Takashi Kei Kishimoto, Ph.D., has been appointed as Chief Scientific Officer. Dr. Kishimoto brings more than 20 years of experience as a pharmaceutical and biotechnology scientist and leader. He will report directly to Werner Cautreels, Ph.D., Chief Executive Officer of Selecta Biosciences.

Back to news